CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase
- PMID: 9443408
CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase
Abstract
Tyrosinase is an antigen that is expressed by normal melanocytes as well as melanoma cells, against which responses by autologous T cells have been detected. Although CD4+ T cells play an important role in tumor immunity in animal tumor models, little information about CD4+ T-cell immunity against human tumors exists. Here, we report that CD4+ T cells from the peripheral blood of a patient with melanoma respond to synthetic peptides derived from nonmutated tyrosinase. T-cell clones were generated that recognized the tyrosinase p386-406 peptide when it was presented by the HLA-DR15 (DRB1*1501) molecule. The CD4+ T-cell clone also recognized autologous EBV-transformed B-lymphoblastoid cell lines that had been pulsed with the lysate of melanoma cells. The synthetic tyrosinase p386-406 peptide was capable of binding to HLA-DR15 (DRB1*1501) molecules on cell surface of DR15 homozygous cells. Thus, the finding that nonmutated tyrosinase peptides are immunogenic in a melanoma patient may provide the basis for the development of cancer immunotherapy, based on knowledge of synthetic tumor-associated peptide antigens.
Similar articles
-
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.J Immunol. 1996 Nov 1;157(9):4079-86. J Immunol. 1996. PMID: 8892642
-
Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2547-54. doi: 10.1167/iovs.05-1547. Invest Ophthalmol Vis Sci. 2006. PMID: 16723469
-
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.Cancer Res. 2000 Sep 1;60(17):4946-52. Cancer Res. 2000. PMID: 10987311
-
New approaches for antirheumatic therapy.Baillieres Clin Rheumatol. 1990 Dec;4(3):649-61. doi: 10.1016/s0950-3579(05)80011-1. Baillieres Clin Rheumatol. 1990. PMID: 2093444 Review.
-
Human tumor antigens recognized by T-cells.Immunol Res. 1997;16(4):313-39. doi: 10.1007/BF02786397. Immunol Res. 1997. PMID: 9439758 Review.
Cited by
-
GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.J Invest Dermatol. 2012 Jan;132(1):154-62. doi: 10.1038/jid.2011.236. Epub 2011 Aug 11. J Invest Dermatol. 2012. PMID: 21833020 Free PMC article.
-
A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes.J Immunother Cancer. 2014 Jul 15;2:23. doi: 10.1186/2051-1426-2-23. eCollection 2014. J Immunother Cancer. 2014. PMID: 25126421 Free PMC article.
-
GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.J Immunol. 2010 Sep 1;185(5):2828-35. doi: 10.4049/jimmunol.1000945. Epub 2010 Jul 28. J Immunol. 2010. PMID: 20668223 Free PMC article.
-
MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.Cancer Immunol Immunother. 2004 Jun;53(6):525-32. doi: 10.1007/s00262-003-0486-4. Epub 2004 Jan 17. Cancer Immunol Immunother. 2004. PMID: 14730400 Free PMC article.
-
Melanosomes and MHC class II antigen-processing compartments: a tinted view of intracellular trafficking and immunity.Immunol Res. 2003;27(2-3):409-26. doi: 10.1385/IR:27:2-3:409. Immunol Res. 2003. PMID: 12857985 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials